{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-22-000700","form_type":"8-K","ticker":"AVXL","cik":"0001314052","company_name":"ANAVEX LIFE SCIENCES CORP.","filed_at":"2022-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.175454+00:00","generated_at":"2026-06-26T08:26:01.463028+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Anavex extends CEO Missling's contract through July 2025; grants 500K options tied to clinical milestones","bullets":["CEO Christopher Missling's employment agreement extended to July 5, 2025.","Base salary increased to $700,000 annually effective July 5, 2022, with target bonus of 20%.","Grant of 500,000 options vesting upon completion of three clinical trial milestones (Alzheimer’s Phase 2b/3, Parkinson’s trial initiation, Fragile X Phase 2/3 initiation).","Options exercise price equals closing price on grant date; accelerated vesting upon change in control."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-22-000700","json":"https://secwatch.observer/filing/0001731122-22-000700.json","markdown":"https://secwatch.observer/filing/0001731122-22-000700.md","text":"https://secwatch.observer/filing/0001731122-22-000700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314052/000173112222000700/0001731122-22-000700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314052/000173112222000700/e3692_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T08:26:01.463028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}